| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42dcb8afd289e295b65f450020cbfdb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-48 |
| filingDate |
2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46fbcbbe51d07351ff571312e117a378
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4763ab1844a7261a5a1276038e9d5ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01e7eee5fe9cdd255b73575d28787f9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5d639d76e34a3df489b296973d80b71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_528113353a4cdde264ae64d5ed5c29ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_176ec1a2713367ee5c4c608cdfbf539e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bc3e4fc80f4387e5936af2304be659a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa668507cbf63d022e98a0097ce31ab5 |
| publicationDate |
2016-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2013399092-A1 |
| titleOfInvention |
Substituted pyrimidine Bmi-1 inhibitors |
| abstract |
Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B -cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein. |
| priorityDate |
2013-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |